The rising tide of billion dollar biotech M&A

M&A has been the talk of biotech this year, brought about by the convergence of the ongoing bear market, the dire need of pharmas to address their patent cliffs, and the growing supply of value-driving innovative assets by biotechs.

Those factors have resulted in a steady growth of billion-dollar-plus biotech takeouts, peaking in 2023, and almost matched in 2024...